Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Beta-blockers inhibit catecholamine-induced sympathetic responses in the heart, decreasing heart rate, contractility, and cardiac output. This leads to cardiac depression and can potentially cause life-threatening bradycardia and heart failure. Despite these risks, they are therapeutically useful as mild antihypertensives and for treating angina pectoris and cardiac arrhythmias.

Nonselective beta-blockers inhibit beta2-receptors in bronchial smooth muscle, causing bronchoconstriction that can be potentially fatal to patients with asthma or obstructive lung diseases. Selective beta1-blockers are preferred in these populations to avoid respiratory complications while maintaining cardiovascular benefits and therapeutic efficacy.

Beta-blockers help control exaggerated sympathetic responses in pheochromocytoma and thyrotoxicosis by blocking catecholamine effects. Additionally, propranolol impedes sympathetically induced lipolysis and insulin release, affecting metabolic processes. These properties make beta-blockers useful in managing sympathetic overactivity associated with these endocrine conditions.

Beta-blockers treat chronic open-angle glaucoma by reducing aqueous humor production, which lowers intraocular pressure and slows disease progression. This mechanism provides an effective therapeutic option for managing glaucoma. Propranolol is particularly noted for this application among beta-blockers used in ophthalmology.

Beta-blocker treatment can cause central nervous system-related effects including fatigue, forgetfulness, sleep disturbances, and depression. These CNS effects occur because beta-blockers cross the blood-brain barrier and affect sympathetic signaling in the brain. Patients should be monitored for these psychological and cognitive changes during therapy.

Propranolol is useful in chronic migraine prevention and acts as an anti-anxiety agent by reducing sympathetic arousal. It is also the drug of choice for treating severe infantile hemangioma, a vascular tumor in infants. These diverse applications demonstrate propranolol's broad pharmacological utility beyond traditional cardiac indications.

Beta-blockers specifically antagonize beta-adrenergic receptors, blocking catecholamine effects on heart rate and contractility. Unlike alpha-receptor antagonists, they do not directly affect vascular smooth muscle tone. Understanding antagonists pharmacological actions receptor blockers helps distinguish their selective effects from broader adrenergic antagonism.